[Prescribed and dispensed in the third trimester of pregnancy drugs: What practices and risks?].
OBJECTIVE
The aim of the study was to describe the prescribing of drugs to pregnant women during the third trimester of pregnancy.


METHODS
The retrospective analysis is interested by pregnant women from August 2009 to April 2011, living in Franche-Comté. The used data are recorded in the database of the French Health Insurance Service. Drugs prescribing were analyzed and classified according to three categories: drugs that are contraindicated, not recommended drugs and drugs that are used. This classification is based on two databases: the Summaries of Product Characteristics of Vidal 2010 and data from the National Security Agency of Medicines. The potential exposure of patients was pointed out.


RESULTS
On 15,027 patients, 80% had a prescription. Six percent of prescriptions containing drugs not recommended and 1% drugs that contraindicated. Therapeutic classes identified are analgesics, anti-infective drugs and medicines supplementing with vitamins and minerals. Contraindicated drugs (10%) are NSAIDs, rubella vaccine, cyclins and ACE inhibitors and ARBs. Approximately 2.7% of women were potentially exposed to these drugs.


CONCLUSIONS
Despite the recommendations of the ANSM, some drugs that are contraindicated are prescribed for pregnant women in their third trimester of pregnancy. In the absence of studies, the decision must be made on a case by case basis by assessing the risk-benefit ratio. Particular care is to bring about the drugs taken in self-medication. Information and advice are key steps to avoid incidents.
Pôle pharmaceutique, CHRU, 3, boulevard Fleming, 25000 Besançon, France. Electronic address: gwenguizmo@hotmail.com.
G
G
Parent
Pôle Mère-Enfant, CHRU, 3, boulevard Fleming, 25000 Besançon, France.
N
N
Mottet
Pôle pharmaceutique, CHRU, 3, boulevard Fleming, 25000 Besançon, France.
P
P
Mairot
Observatoire du médicament et des innovations thérapeutiques (OMEDIT) de Franche-Comté, Agence régionale de santé, 3, avenue Louise-Michel, 25000 Besançon, France.
F
F
Baudier
Observatoire du médicament et des innovations thérapeutiques (OMEDIT) de Franche-Comté, Agence régionale de santé, 3, avenue Louise-Michel, 25000 Besançon, France.
D
D
Carel
Observatoire du médicament et des innovations thérapeutiques (OMEDIT) de Franche-Comté, Agence régionale de santé, 3, avenue Louise-Michel, 25000 Besançon, France.
M
M
Goguey
Pôle Mère-Enfant, CHRU, 3, boulevard Fleming, 25000 Besançon, France.
D
D
Riethmuller
Pôle pharmaceutique, CHRU, 3, boulevard Fleming, 25000 Besançon, France; Observatoire du médicament et des innovations thérapeutiques (OMEDIT) de Franche-Comté, Agence régionale de santé, 3, avenue Louise-Michel, 25000 Besançon, France.
S
S
Limat
D000328:Adult; D011307:Drug Prescriptions / Q000592:standards / Q000706:statistics & numerical data*; D005260:Female; D005602:France; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000706:statistics & numerical data*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011263:Pregnancy Trimester, Third / Q000187:drug effects*; D012189:Retrospective Studies; D012306:Risk
Drugs; Grossesse; Médicaments; Practices; Pratiques; Pregnancy; Risks; Risques